Picture loading failed.

Pre-Made Relfovetmab biosimilar, Feline Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-477-1mg 1mg 3090
GMP-Bios-ab-477-10mg 10mg 21890
GMP-Bios-ab-477-100mg 100mg 148000
GMP-Bios-ab-477-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Relfovetmab biosimilar, Feline Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody
INN Name Relfovetmab
TargetNGF
FormatFeline Whole mAb
DerivationFelinized
Species ReactivityFeline
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Unknown
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
Companiesna
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna